Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$96.55
-4.3%
$116.01
$5.69
$148.83
$8.04B0.692.86 million shs1.16 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$264.48
+1.6%
$299.42
$239.25
$385.22
$28.56B0.49256,995 shs260,934 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$153.87
+3.1%
$140.76
$34.00
$166.50
$31.73B1.42.79 million shs1.58 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$34.58
+0.0%
$33.28
$14.99
$37.35
$39.74B0.845.70 million shs5.93 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-4.28%-4.90%-20.80%-16.41%+1,201.21%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+1.62%-2.08%-16.45%-6.89%+0.79%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+3.11%+3.11%+2.62%+62.21%+277.22%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+0.07%+1.06%-4.64%+21.16%+99.87%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$96.55
-4.3%
$116.01
$5.69
$148.83
$8.04B0.692.86 million shs1.16 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$264.48
+1.6%
$299.42
$239.25
$385.22
$28.56B0.49256,995 shs260,934 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$153.87
+3.1%
$140.76
$34.00
$166.50
$31.73B1.42.79 million shs1.58 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$34.58
+0.0%
$33.28
$14.99
$37.35
$39.74B0.845.70 million shs5.93 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-4.28%-4.90%-20.80%-16.41%+1,201.21%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+1.62%-2.08%-16.45%-6.89%+0.79%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+3.11%+3.11%+2.62%+62.21%+277.22%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+0.07%+1.06%-4.64%+21.16%+99.87%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.73
Moderate Buy$130.0834.72% Upside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
2.93
Moderate Buy$390.0047.46% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$123.72-19.59% Downside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.80
Moderate Buy$41.7820.83% Upside

Current Analyst Ratings Breakdown

Latest ABVX, TEVA, RVMD, and ONC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
UpgradeHoldStrong-Buy
6/3/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Set Price Target$136.00
6/3/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingOutperform
6/2/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Lower Price TargetBuy$140.00 ➝ $135.00
6/2/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Lower Price TargetOverweight$145.00 ➝ $132.00
6/2/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingOutperform
6/2/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
DowngradeBuyHold$160.00 ➝ $90.00
6/2/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Boost Price TargetMarket Outperform$131.00 ➝ $187.00
6/2/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
UpgradeUnderperformNeutral$110.00 ➝ $90.00
6/2/2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
Reiterated RatingBuy$150.00
6/2/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOutperform$425.00 ➝ $436.00
(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$5.34B5.43$3.97 per share66.59$39.77 per share6.65
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M2,824.94N/AN/A$8.44 per share18.23
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$17.26B2.30$3.73 per share9.27$6.88 per share5.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%N/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$4.4759.1725.05N/A8.94%12.06%6.69%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$7.07N/AN/AN/AN/A-83.22%-59.06%8/5/2026 (Estimated)
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$1.41B$1.3326.0011.373.539.01%43.53%8.19%7/29/2026 (Estimated)

Latest ABVX, TEVA, RVMD, and ONC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2026Q1 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million
5/6/2026Q1 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A
4/29/2026Q1 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.50$0.53+$0.03$0.31$3.79 billion$3.98 billion
4/1/2026Q1 2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/A$0.25N/A$1.95N/A$1.51 billion
3/31/2026Q1 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/A$0.53N/A$0.31N/A$3.98 billion
3/23/2026Q4 2025
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
8.25
8.25
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.20
3.64
3.27
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.19
6.80
6.80
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
1.70
1.01
0.78

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.19%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.54%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
6179.69 millionN/ANot Optionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.72 million102.93 millionN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250212.60 million196.44 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
33,9501.15 billion1.14 billionOptionable

Recent News About These Companies

Is Amneal a Buy Before Rytary Generic Erosion?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abivax stock logo

Abivax NASDAQ:ABVX

$96.55 -4.32 (-4.28%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$98.22 +1.67 (+1.73%)
As of 06/12/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$264.48 +4.21 (+1.62%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$264.53 +0.05 (+0.02%)
As of 06/12/2026 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$153.87 +4.64 (+3.11%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$153.69 -0.18 (-0.12%)
As of 06/12/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$34.58 +0.02 (+0.04%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$34.57 0.00 (0.00%)
As of 06/12/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.